問卷

TPIDB > Search Result

Search Result

篩選

List

64Cases

2022-03-09 - 2026-12-15

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-05-10 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-11-30 - 2027-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-03-01 - 2028-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-10-02 - 2028-01-05

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-04-01 - 2025-11-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting4Sites

Terminated1Sites

2018-08-01 - 2026-12-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2021-06-01 - 2023-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2015-12-10 - 2019-12-31

IIT

Phase II

A PHASE II, OPEN LABEL, MULTICENTER STUDY OF BEVACIZUMAB IN COMBINATION WITH ERLOTINIB VERSUS ERLOTINIB ALONE IN PATIENTS WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES.
  • Condition/Disease

    NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES

  • Test Drug

    (1)Avastin; (2) Erlotinib

Participate Sites
3Sites

Recruiting3Sites

2019-04-01 - 2022-12-31

Phase II

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)
  • Condition/Disease

    non-squamous non-small cell lung cancer

  • Test Drug

    Durvalumab、Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

夏德椿
China Medical University Hospital

Division of General Internal Medicine